Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Cell Line, Tumor
Cell Proliferation
/ genetics
Collagen
/ metabolism
DNA Methylation
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Melanoma
/ genetics
Procollagen-Proline Dioxygenase
/ genetics
Prolyl Hydroxylases
/ genetics
Protein Processing, Post-Translational
/ genetics
Reference Values
Skin Neoplasms
/ genetics
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
16
09
2017
revised:
24
09
2018
accepted:
01
10
2018
pubmed:
20
11
2018
medline:
8
5
2020
entrez:
20
11
2018
Statut:
ppublish
Résumé
Appropriate post-translational processing of collagen requires prolyl hydroxylation, catalyzed by collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase, and is essential for normal cell function. Here we have investigated the expression, transcriptional regulation, and function of the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families in melanoma. We show that the collagen prolyl 3-hydroxylase family exemplified by Leprel1 and Leprel2 is subject to methylation-dependent transcriptional silencing in primary and metastatic melanoma consistent with a tumor suppressor function. In contrast, although there is transcriptional silencing of P4HA3 in a subset of melanomas, the collagen prolyl 4-hydroxylase family members P4HA1, P4HA2, and P4HA3 are often overexpressed in melanoma, expression being prognostic of worse clinical outcomes. Consistent with tumor suppressor function, ectopic expression of Leprel1 and Leprel2 inhibits melanoma proliferation, whereas P4HA2 and P4HA3 increase proliferation, and particularly invasiveness, of melanoma cells. Pharmacological inhibition with multiple selective collagen prolyl 4-hydroxylase inhibitors reduces proliferation and inhibits invasiveness of melanoma cells. Together, our data identify the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families as potentially important regulators of melanoma growth and invasiveness and suggest that selective inhibition of collagen prolyl 4-hydroxylase is an attractive strategy to reduce the invasive properties of melanoma cells.
Identifiants
pubmed: 30452903
pii: S0022-202X(18)32822-7
doi: 10.1016/j.jid.2018.10.038
pmc: PMC7015666
mid: NIHMS1068465
pii:
doi:
Substances chimiques
Collagen
9007-34-5
Prolyl Hydroxylases
EC 1.14.11.-
Procollagen-Proline Dioxygenase
EC 1.14.11.2
P3H2 protein, human
EC 1.14.11.7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118-1126Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR044276
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Med Chem. 2018 Dec 13;61(23):10403-10411
pubmed: 29986141
Br J Cancer. 2012 Oct 9;107(8):1423-32
pubmed: 22955849
Br J Cancer. 2009 May 19;100(10):1687-96
pubmed: 19436308
Oncotarget. 2015 May 20;6(14):12297-309
pubmed: 25909218
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Clin Cancer Res. 2009 Mar 1;15(5):1801-7
pubmed: 19223509
J Invest Dermatol. 2013 May;133(5):1278-85
pubmed: 23407390
ACS Chem Biol. 2016 Jan 15;11(1):193-9
pubmed: 26535807
Eur J Biochem. 2001 Oct;268(20):5300-9
pubmed: 11606192
J Cell Biol. 1998 Jul 27;142(2):587-94
pubmed: 9679154
J Biol Chem. 2011 Sep 2;286(35):30662-9
pubmed: 21757687
BMC Cancer. 2014 Jan 02;14:1
pubmed: 24383403
Annu Rev Biochem. 2009;78:929-58
pubmed: 19344236
Nat Cell Biol. 2013 Jun;15(6):677-87
pubmed: 23644467
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Future Oncol. 2017 Aug;13(20):1755-1766
pubmed: 28587477
Br J Cancer. 2012 Apr 10;106(8):1446-52
pubmed: 22454080
Genes Dev. 2012 Sep 15;26(18):2038-49
pubmed: 22925884
Ann Med. 2008;40(6):402-17
pubmed: 19160570
Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106-24
pubmed: 20199358
Science. 2006 Aug 18;313(5789):968-71
pubmed: 16917063
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Circulation. 2003 Aug 5;108(5):508-11
pubmed: 12874193
Cancer Res. 2013 Jun 1;73(11):3285-96
pubmed: 23539444